CClinicalTrials.gg
Status unknownNCT03159338Updated Dec 7, 2017

Platelet-rich Fibrin on Nerve Regeneration After Bilateral Sagittal Split Osteotomy

An interventional study of Platelet rich fibrin and Placebo in Paresthesia, Anesthesia, Local and Neurosensory Disorder, sponsored by Shiraz University of Medical Sciences. Status unknown at 2 sites in Iran, Islamic Republic of. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-12-07.

Sponsored by Shiraz University of Medical Sciences · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Patients who have mandibular deformity and will undergo bilateral sagittal split osteotomy will be included in the study.One side of the osteotomies randomly will be considered as study group and another side as a control group.In the study group , platelet rich fibrin will be placed after osteotomy and before rigid fixation.In the control group, fixation will be done without Platelet-rich Fibrin (PRF).Neurosensory disturbance will be evaluated 6 and 12 months after surgeries.

Read the detailed description

Patients who have mandibular deformity and will undergo bilateral sagittal split osteotomy will be included in the study.One side of the osteotomies randomly will be considered as study group and another side as a control group.In the study group , platelet rich fibrin will be placed after osteotomy and before rigid fixation.In the control group fixation will be done without Platelet-rich Fibrin. Before starting the surgical procedure, 20 mL of venous blood will take and placed in a centrifuge for 12 minutes with 28000rpm. After centrifugation, the cap will be removed from each tube and they will be placed into a sterile rack L-PRF™. Fibrin matrix will prepare. The L-PRF™ will be removed from the tube. Then, the clot right beneath the red blood cell clot will be placed on the surface tray and covered. Five minutes will be waited before removing and using the fibrin matrix.Neurosensory disturbance will be evaluated in 6 and 12 months after osteotomies by two-point discrimination (TPD) test and pin tactile discrimination(PTD) tests.

02

Conditions studied

  • Paresthesia
  • Anesthesia, Local
  • Neurosensory Disorder

Browse trials for

03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients who have class II or III deformity and will undergo bilateral sagittal split osteotomy

Exclusion criteria

Exclusion Criteria:

  • Patients who have bad split or obvious nerve injury during surgery will be removed from study inclusion
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
25 participants (estimated)

Study arms

  • Active comparator
    treatment group

    One side of osteotomies will be considered as a treatment arm (randomly) which Platelet rich fibrin will be used with rigid fixation

    Biological: Platelet rich fibrin

  • Placebo comparator
    Control group

    In control site , placebo gel will be placed before rigid fixation

    Biological: Placebo

Interventions

  • BiologicalPlatelet rich fibrin

    Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.

  • BiologicalPlacebo

    In control group , after spliting the osteotomy site before fixation a placebo gel will be placed

05

What researchers measure

Primary outcomes

  1. Two-point discrimination (TPD) test

    Two point discrimination will be measured based on the distance of two points (mm)

    Time frame: TPD will be assessed after 6 months

  2. Two-point discrimination

    Two point discrimination will be measured based on the distance of two points (mm)

    Time frame: Two-point discrimination will be evaluated after12 months intervals

06

Study locations

1 of 2 sites recruiting
  • Shiraz university of medical sciences
    Shiraz, Iran, Islamic Republic of
    • Reza Tabrizi, DMD · Contact · tabmed@gmail.com · 09125850829
    • · Contact · 00987136280458
    • Reza Tabrizi · Principal investigator
    Not yet recruiting
  • Taleghani Hospital
    Tehran, Iran, Islamic Republic of
    • Fahimeh Akhlaghi, DMD · Contact
    Recruiting
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03159338
Lead sponsor
Shiraz University of Medical Sciences
Collaborators
Shahid Beheshti University of Medical Sciences
Responsible party
Reza Tabrizi (Assistant professor of oral and maxillofacial surgery, Shiraz University of Medical Sciences) — Principal investigator
First posted
May 18, 2017
Start date
Sep 1, 2017
Primary completion
May 30, 2018 (estimated)
Completion
Sep 30, 2018 (estimated)
Last update
Dec 7, 2017

Study contacts

Reza Tabrizi, DMD
Contact
tabmed@gmail.com
+989125850829
Reza Tabrizi, DMD
principal investigator · Shiraz University of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion